Liver Cancer

Liver Cancer

肝癌

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《Liver Cancer》是由S. Karger AG出版社于2012年创办的英文国际期刊(ISSN: 2235-1795,E-ISSN: 1664-5553),该期刊长期致力于胃肠肝病学领域的创新研究,主要研究方向为Oncology-Medicine。作为SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA未开放获取模式(OA占比1%),以发表胃肠肝病学领域等方向的原创性研究为核心(研究类文章占比89.80%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在49篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Liver Cancer审稿周期约为 16 Weeks 。该刊近年未被列入国际预警名单,年发文量约49篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 49 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 ONCOLOGY 肿瘤学
1区 1区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
1区 2区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 9 / 143

94.1%

学科:ONCOLOGY SCIE Q1 23 / 322

93%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 10 / 143

93.36%

学科:ONCOLOGY SCIE Q1 22 / 322

93.32%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:20.8 SJR:3.599 SNIP:2.917
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q1 19 / 404

95%

大类:Medicine 小类:Hepatology Q1 6 / 82

93%

期刊发文

  • First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis

    Author: Fong, Khi Yung; Zhao, Joseph Jonathan; Sultana, Rehena; Lee, Joycelyn Jie Xin; Lee, Suat Ying; Chan, Stephen Lam; Yau, Thomas; Tai, David Wai Meng; Sundar, Raghav; Too, Chow Wei

    Journal: LIVER CANCER. 2023; Vol. 12, Issue 1, pp. 7-18. DOI: 10.1159/000526639

  • Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab

    Author: Hsu, Chiun; Ducreux, Michel; Zhu, Andrew X.; Qin, Shukui; Ikeda, Masafumi; Kim, Tae-You; Galle, Peter R.; Finn, Richard S.; Chen, Ethan; Ma, Ning; Hu, Youyou; Li, Lindong; Cheng, Ann-Lii

    Journal: LIVER CANCER. 2023; Vol. 12, Issue 1, pp. 44-56. DOI: 10.1159/000525499

  • Dietary fat composition affects hepatic angiogenesis and lymphangiogenesis in HCV core gene transgenic mice

    Author: Diao, Pan; Wang, Yaping; Jia, Fangping; Wang, Xiaojing; Hu, Xiao; Kimura, Takefumi; Sato, Yoshiko; Moriya, Kyoji; Koike, Kazuhiko; Nakayama, Jun; Tanaka, Naoki

    Journal: LIVER CANCER. 2023; Vol. 12, Issue 1, pp. 57-71. DOI: 10.1159/000525546

  • Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

    Author: Ren, Zhenggang; Ducreux, Michel; Abou-Alfa, Ghassan K.; Merle, Philippe; Fang, Weijia; Edeline, Julien; Li, Zhiwei; Wu, Lihua; Assenat, Eric; Hu, Sheng; Rimassa, Lorenza; Zhang, Tao; Blanc, Jean-Frederic; Pan, Hongming; Ross, Paul; Yen, Chia-Jui; Tran, Albert; Shao, Guoliang; Bouattour, Mohamed; Chen, Yajin; Meyer, Tim; Hou, Jinlin; Tougeron, David; Bai, Yuxian; Hou, Ming-Mo; Meng, Zhiqiang; Wu, John; Li, Vincent; Chica-Duque, Sandra; Cheng, Ann-Lii

    Journal: LIVER CANCER. 2023; Vol. 12, Issue 1, pp. 72-84. DOI: 10.1159/000527175

  • Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management

    Author: Ye, Liangtao; Schneider, Julia S. S.; Ben Khaled, Najib; Schirmacher, Peter; Seifert, Carolin; Frey, Lea; He, Yulong; Geier, Andreas; De Toni, Enrico N. N.; Zhang, Changhua; Reiter, Florian P. P.

    Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000530700

  • Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review

    Author: Vogel, Arndt; Kelley, Robin Katie; Johnson, Philip; Merle, Philippe; Yau, Thomas; Kudo, Masatoshi; Meyer, Tim; Rimassa, Lorenza

    Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000529173

  • Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study

    Author: Kudo, Masatoshi; Aoki, Tomoko; Ueshima, Kazuomi; Tsuchiya, Kaoru; Morita, Masahiro; Chishina, Hirokazu; Takita, Masahiro; Hagiwara, Satoru; Minami, Yasunori; Ida, Hiroshi; Nishida, Naoshi; Ogawa, Chikara; Tomonari, Tetsu; Nakamura, Noriaki; Kuroda, Hidekatsu; Takebe, Atsushi; Takeyama, Yoshifumi; Hidaka, Masaaki; Eguchi, Susumu; Chan, Stephen L.; Kurosaki, Masayuki; Izumi, Namiki

    Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000529574

  • Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

    Author: Merle, Philippe; Kudo, Masatoshi; Edeline, Julien; Bouattour, Mohamed; Cheng, Ann-Lii; Chan, Stephen Lam; Yau, Thomas; Garrido, Marcelo; Knox, Jennifer; Daniele, Bruno; Breder, Valeriy; Lim, Ho Yeong; Ogasawara, Sadahisa; Cattan, Stephane; Chao, Yee; Siegel, Abby B.; Martinez-Forero, Ivan; Wei, Ziwen; Liu, Chih-Chin; Finn, Richard S.

    Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000529636